CASC3 and neoplasm: Both 8226 WT or 8226/BTZ RFWD2 KD tumor expansion were outstandingly lagged behind their corresponding partner control, indicating that targeting RFWD2 could repress tumor expansion and overcome BTZ resistance both in vitro and in vivo.